A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance
AC Huang, R Zappasodi - Nature immunology, 2022 - nature.com
Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …
Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy
Among new treatment approaches for patients with cancer, few have accelerated as quickly
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …
Neoadjuvant relatlimab and nivolumab in resectable melanoma
RN Amaria, M Postow, EM Burton, MT Tetzlaff, MI Ross… - Nature, 2022 - nature.com
Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …
Immune checkpoint inhibitors in melanoma
Immune checkpoint inhibitors target the dysfunctional immune system, to induce cancer-cell
killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and …
killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and …
Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome
RC Simpson, ER Shanahan, M Batten, ILM Reijers… - Nature medicine, 2022 - nature.com
The gut microbiota shapes the response to immune checkpoint inhibitors (ICIs) in cancer,
however dietary and geographic influences have not been well-studied in prospective trials …
however dietary and geographic influences have not been well-studied in prospective trials …
Immunosurveillance in clinical cancer management
The progression of cancer involves a critical step in which malignant cells escape from
control by the immune system. Antineoplastic agents are particularly efficient when they …
control by the immune system. Antineoplastic agents are particularly efficient when they …
Neoadjuvant checkpoint blockade for cancer immunotherapy
BACKGROUND Immunotherapies that target the interaction of programmed death 1 (PD-1)
with its ligands, PD-L1 and PD-L2, have ushered in the modern oncology era. The PD-1 …
with its ligands, PD-L1 and PD-L2, have ushered in the modern oncology era. The PD-1 …
Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment
Microsatellite unstable (MSI) colorectal cancers (CRCs) are due to DNA mismatch repair
(MMR) deficiency and occurs in15% of non-metastatic diseases and 5% in the metastatic …
(MMR) deficiency and occurs in15% of non-metastatic diseases and 5% in the metastatic …
Tumor-draining lymph nodes: At the crossroads of metastasis and immunity
Early engagement of the lymphatic system by solid tumors in peripheral, nonlymphoid
tissues is a clinical hallmark of cancer and often forecasts poor prognosis. The significance …
tissues is a clinical hallmark of cancer and often forecasts poor prognosis. The significance …
Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG …
PURPOSE We conducted the phase III double-blind European Organisation for Research
and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab …
and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab …